Cancer’s Vulnerability is Our Strength
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Scientific Approach
At Cyteir, we employ an integrated target discovery approach that incorporates a critical evaluation of the target biology with internal and external information from a variety of genetic and chemical synthetic lethality screens to fuel our drug discovery and development pipeline. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.
Cyteir’s Culture
With a pioneering spirit, putting patients first, we advance science passionately and collaboratively, in a fun learning environment. We value open, honest and transparent communication. We work diligently with respect for each other with a sense of urgency, integrity, accountability and purpose.
“Cyteir is a clinical stage oncology company that’s focused entirely on the discovery and development of next-generation synthetically lethal therapies for the treatment of cancer. We’re using our expertise in translating new biological discoveries to advance a pipeline of novel drugs that create synthetic lethality and target these cancer vulnerabilities.”
Markus Renschler, MD
President and Chief Executive Officer